News & Analysis on Clinical Trial Services & Contract Research And Development
As clinical trials “continue to shift to emerging markets,” the translation company Welocalize has acquired Global Language Solutions (GLS) to further support its clients’ linguistic validation processes.
Fast-tracked Factor Xa inhibitor is being made for Portola by CMC Biologics and Lonza
Portola Pharmaceuticals says it was "caught off guard" after the US FDA raised manufacturing concerns in a complete response letter for its Factor Xa inhibitor, AndexXa.
Actavis has recalled five lots of a diabetes drug glipizide made by Patheon after tests revealed that the tablets did not meet specifications.
An Indian facility owned by Pfizer’s Hospira unit has been banned from supplying some drugs to the EU after MHRA inspectors found breaches of manufacturing regulations.
BioPharma Services has acquired intellectual property and human resource assets from Bioanalytical Laboratory Services (BLS), including a list of validated assays.
The international private equity firm, Cinven, is set to purchase Bioclinica, marking the company’s latest in a series of purchases as industry consolidation continues.
Siegfried Holding AG has attributed a surge in API sales to the drug ingredients business it bought from BASF last year, but says that integration costs hurt profits.